ESLA
HEALTHCAREEstrella Immunopharma Inc
$1.30-0.11 (-7.57%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ESLA Today?
No stock-specific AI insight has been generated for ESLA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.78$3.15
$1.30
Fundamentals
Market Cap$55M
P/E Ratio—
EPS$-0.35
Dividend Yield—
Dividend / Share—
ROE-2.7%
Profit Margin—
Debt / Equity—
Trading
Volume51K
Avg Volume (10D)—
Shares Outstanding42.7M
ESLA News
16 articles- Estrella Immunopharma to Participate in the D. Boral Capital Global ConferenceYahoo Finance·May 5, 2026
- Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap ResearchYahoo Finance·Mar 23, 2026
- ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-TYahoo Finance·Mar 18, 2026
- ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHLYahoo Finance·Feb 9, 2026
- Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®Yahoo Finance·Feb 9, 2026
- Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®Yahoo Finance·Feb 3, 2026
- Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private PlacementYahoo Finance·Jan 6, 2026
- Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesYahoo Finance·Jan 5, 2026
- Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB RecommendationYahoo Finance·Dec 4, 2025
- Top 100 Stocks to Buy: Two Penny Stocks Moved Up 51 Spots. Should You Buy Either?Barchart·Nov 4, 2025
- Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable PatientsYahoo Finance·Nov 3, 2025
- Estrella Immunopharma Regains Compliance with Nasdaq Listing RequirementsYahoo Finance·Oct 6, 2025
- Is Estrella Immunopharma (NASDAQ:ESLA) In A Good Position To Deliver On Growth Plans?Yahoo Finance·Aug 14, 2025
- Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaYahoo Finance·Jun 5, 2025
- Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity FinancingYahoo Finance·Jun 3, 2025
- Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s LymphomasYahoo Finance·May 29, 2025
All 16 articles loaded
Price Data
Open$1.50
Previous Close$1.41
Day High$1.55
Day Low$1.39
52 Week High$3.15
52 Week Low$0.78
52-Week Range
$0.78$3.15
$1.30
Fundamentals
Market Cap$55M
P/E Ratio—
EPS$-0.35
Dividend Yield—
Dividend / Share—
ROE-2.7%
Profit Margin—
Debt / Equity—
Trading
Volume51K
Avg Volume (10D)—
Shares Outstanding42.7M
About Estrella Immunopharma Inc
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company is headquartered in EmeryVille, California.
Listed October 2, 2023
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—